Apogee Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Good morning, everyone. Thank you so much for joining us. It's my pleasure to introduce the Apogee team. With us, we have Jane Pritchett Henderson, Chief Financial Officer; and Jeff Hartness, Chief Commercial Officer. Thank you for joining us.
Questions & Answers
Maybe to start here, on the back of a few key data sets that have read out this year, including the 52-week zumi data in atopic dermatitis and recent dose escalation data in the disease as well, can you outline how the company is positioned in the second half and beyond and walk through the key near-term catalysts?
Yes, absolutely, and thank you for having us, Salveen. Apogee is developing zumilokibart, our IL-13 targeting antibody across type 2 inflammatory diseases. Our first priority is moderate to severe atopic dermatitis. It is the largest of the I&I indications. It
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
